Both are standard safety markers in any thorough metabolic baseline panel
Funding This study was supported by the Medical Science Research Program of Hebei Province (20220709), the Government Funded Clinical Medicine Excellent Talent Training Project (ZF2022034), and the Hebei Natural Science Foundation (H2022316005)

References PMC Once-Weekly Semaglutide for Weight Management: A Clinical Review Comprehensive review of Semaglutides mechanism, efficacy, and safety in weight management (clinical data, half-life, GLP-1 receptor activation, weekly dosing) NCBI Bookshelf Semaglutide (StatPearls) Comprehensive pharmacology, clinical uses, dosing strategies, adverse effects, and contraindications for Semaglutide Mayo Clinic Semaglutide (Subcutaneous Route) Clinical guidance on Semaglutide administration, side effects, dosing, and patient information including weekly protocol PMC Semaglutide 2.4 mg for Weight Loss: Clinical Evidence Evidence-based review of Semaglutide 2.4 mg weekly maintenance dosing and clinical outcomes in obesity treatment PubMed Cardiovascular Outcomes with Semaglutide Long-term cardiovascular safety and benefits observed in Semaglutide clinical trials Journal of the Royal Society Interface (2017) Peer-reviewed review of formulation, temperature, agitation, lyophilization, and other factors that affect peptide stability

Nature 435: 839843 Guil S, Cceres JF (2007) The multifunctional RNAbinding protein hnRNP A1 is required for processing of miR18a
After the blood collection, mice were flushed with ice-cold PBS to remove residual blood